Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

RedHill Biopharma secures $6 million via a private placement, aiming for up to $19.4 million. The offering is led by H.C. Wainwright & Co.

PUBLIC · RDHLJun 18, 2026•about 1 month ago

Amount Raised

$6 Million

Round Type

Post-IPO Equity

RaleighManufacturingBiotechnologyHealthcareSoftwareHealth CareScience And Engineering

Investors

H.C. Wainwright & Co.

Description

RedHill Biopharma Ltd. announced a definitive agreement for a private placement, expecting $6 million upfront. The company could potentially raise an additional $13.4 million through the exercise of warrants. The offering will close on June 22, 2026, pending customary conditions

Company Information

Company

RedHill Biopharma

Location

Raleigh, North Carolina, United States

About

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal, infectious, and oncological diseases in the U.S. The company markets Talicia®, an FDA-approved treatment for H. pylori infection, and is advancing late-stage programs including opaganib, a first-in-class SPHK2 inhibitor; RHB-204 for Crohn’s disease and nontuberculous mycobacteria (NTM) infections; RHB-107 (upamostat) for COVID-19 and inflammatory diseases; and RHB-102 for nausea, vomiting, and IBS-D.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for RedHill Biopharma's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching RedHill Biopharma? See every signal — funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan